FINWIRES · TerminalLIVE
FINWIRES

$INDV

8 stories mentioning INDVUpdated 4h ago

Every FINWIRES story that references INDV, newest first.

What are analysts saying about INDV?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on INDV?

Sectors

Sector Update: Healthcare Stocks Edge Higher Pre-Bell Thursday

Healthcare stocks were edging higher pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.6% and the iShares Biotechnology ETF (IBB) advancing by 1.3%.Nuvation Bio (NUVB) stock was up more than 3% after the company said the FDA has approved its supplemental New Drug Application for IBTROZI (taletrectinib), a ROS1 inhibitor for locally advanced or metastatic ROS1-positive non-small cell lung cancer.Indivior Pharmaceuticals (INDV) shares were up more than 3% after the company said its board has declared a special cash dividend of $8.13 per share to holders of record as of Oct. 30.IDEXX Laboratories (IDXX) has expanded its Faecal Dx antigen testing platform in the UK to detect taeniid tapeworms, including Taenia and Echinococcus species, the company said. IDEXX Laboratories stock was up more than 1% premarket.

$IBB$IDXX$INDV$NUVB$XLV
Sectors

Sector Update: Healthcare Stocks Edge Higher Pre-Bell Wednesday

Healthcare stocks were edging higher pre-bell Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) advancing by 0.9%.Twist Bioscience (TWST) stock was up more than 3% after the company said it has agreed to provide antibody characterization data services to Lilly TuneLab, an AI/ML drug discovery platform created by Eli Lilly (LLY).Indivior Pharmaceuticals (INDV) and Reckitt Benckiser Healthcare have agreed to accelerate the termination date of their copacker supply agreement for Suboxone and Subutex tablets on Jan. 15, 2027, Indivior said in a regulatory filing. Shares of Indivior Pharmaceuticals were up more than 1% premarket.Abeona Therapeutics (ABEO) stock was up more than 2% after the company said the University of Florida Health in Gainesville has become the eighth Qualified Treatment Center for administering ZEVASKYN, its gene-modified cellular sheet therapy for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa.

$ABEO$IBB$INDV$LLY$TWST$XLV
Sectors

Sector Update: Healthcare Stocks Rise Pre-Bell Monday

Healthcare stocks were rising pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.2% higher and the iShares Biotechnology ETF (IBB) advancing by 0.8%.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a pharmaceutical company valued at nearly $400 billion, the Financial Times reported, citing unnamed people familiar with the matter. Astrazeneca stock was 7% lower, while Bristol Myers Squibb shares were up more than 3% premarket.Supernus Pharmaceuticals (SUPN) and Indivior Pharmaceuticals (INDV) said they will merge in a tax-free, all-stock deal. Shares of Supernus Pharmaceuticals were up more than 14% and Indivior Pharmaceuticals stock advanced past 1% pre-bell.KKR (KKR) entered into a definitive agreement to acquire Integer (ITGR) through affiliated funds in an all-cash transaction at an enterprise value of $5.7 billion, the companies said. Integer shares were up more than 2% premarket.

$AZN$BMY$IBB$INDV$ITGR$KKR$SUPN$XLV
Research

Barclays Initiates Indivior at Overweight With $46 Price Target

Indivior (INDV) has an average rating of buy and mean price target of $50.83, according to analysts polled by FactSet.

$INDV
Insider Trading

Indivior Pharmaceuticals Insider Sold Shares Worth $1,357,200, According to a Recent SEC Filing

Ryan Preblick, Chief Financial Officer, on June 08, 2026, sold 36,000 shares in Indivior Pharmaceuticals (INDV) for $1,357,200. Following the Form 4 filing with the SEC, Preblick has control over a total of 284,751 common shares of the company, with 284,751 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1625297/000201486626000011/xslF345X05/wk-form4_1781085864.xml

$INDV
Sectors

Sector Update: Health Care Stocks Flat to Lower Premarket Monday

Health care stocks were flat to lower premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.4%.Indivior Pharmaceuticals (INDV) shares were up more than 2% after the company said it has entered into a $175 million accelerated share repurchase agreement with Barclays Bank, to be executed under the company's existing $400 million buyback program.Axsome Therapeutics (AXSM) stock was up more than 3% after the company reported higher Q1 revenue while its loss per share increased.ADMA Biologics (ADMA) shares were 0.8% higher after the company said it received US Food and Drug Administration approval for the supplemental biologics license application to expand the label of its Asceniv therapy.

$ADMA$AXSM$IBB$INDV$XLV
Sectors

Sector Update: Health Care

Health care stocks were flat to lower premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.5%.Indivior Pharmaceuticals (INDV) shares were up more than 3% after the company said it has entered into a $175 million accelerated share repurchase agreement with Barclays Bank, to be executed under the company's existing $400 million buyback program.

$INDV
Wire

Indivior Shares Rise After Q1 Adjusted Earnings, Net Revenue Beat Estimates; Lifts 2026 Net Revenue Outlook

Indivior Pharmaceuticals (INDV) shares were rising past 4% in Thursday trading after it reported Q1 adjusted earnings and net revenue that rose year on year and beat analysts' estimates, and also lifted its 2026 net revenue guidance.The company reported Q1 adjusted earnings Thursday of $0.96 per diluted share, up from $0.45 a year earlier.Analysts polled by FactSet expected $0.66.Net revenue for the quarter ended March 31 was $317 million, up from $266 million a year earlier.Analysts surveyed by FactSet expected $272.8 million.The company said it now expects 2026 net revenue of $1.215 billion to $1.285 billion, up from its previous outlook of $1.125 billion to $1.195 billion.Analysts polled by FactSet expect $1.16 billion.Price: $35.94, Change: $+1.79, Percent Change: +5.24%

$INDV

Track with the FINWIRES app suite

FolioX
FolioX
Track INDV in your portfolio
WheelAI
WheelAI
Analyze INDV options with the wheel strategy
StockInsider
StockInsider
See market sentiment on INDV